Evidence-Based Medicine and Real-World Data in Allergen Immunotherapy Today and in the Future: Quality or Quantity?
- 7 Downloads
Purpose of the review
Data obtained from controlled clinical trials remains the gold standard for the evaluation of treatment efficacy and safety. This information is used in systematic reviews and meta-analysis providing data for evidence-based medicine (EBM) statements and conclusions which are preferred by regulatory and academic groups when decisions and recommendations need to be given.
The quantity and diversity of real-world data (RWD) have been increasing exponentially as technology and integrated electronic medical records have made this information increasingly accessible and useful for outcomes research and regulatory purposes.
There are increasing interest and potential for converting RWD into real-world evidence that, through careful analysis and interpretation, can be used to inform healthcare decision-making.
In this article, we present a concise summary of the literature about the role of EBM and RWD in allergen immunotherapy. We are aiming to evaluate their influence on current and future decisions for good clinical practice parameter recommendations.
KeywordsEvidence-based medicine Real-world data Allergen immunotherapy
Compliance with ethical standards
Conflict of interest
Dr. Demoly reports personal fees from ALK, personal fees from StallergènesGreer, personal fees from Iqvia, personal fees from Chiesi, personal fees from AstraZeneca, personal fees from ThermoFisherScientific, personal fees from Sanofi-Regeneron, personal fees from Ménarini, personal fees from Bausch&Lomb and personal fees from Novartis, outside the submitted work.
Prof Dr. Moisés A. Calderon has received an honorarium as speaker from AKL-Abello, AKL-USA, ALK-Canda, Stallergenes Greer and HAL-Allergy and as an advisory board member from ALK-Abello, Stallergenes Greer, HAL-Allergy and ASIT-Biotech.
Dr. Rico has nothing to disclose.
Human and animal rights and informed consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 3.•• Calderon MA, Casale TB, Togias A, Bousquet J, Durham SR, Demoly P. Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. J Allergy Clin Immunol. 2011;127:30–8. The paper provides a critical global view of AIT assessing different clinical and research issues.CrossRefGoogle Scholar
- 4.Calderon MA. Meta-analyses of specific immunotherapy trials. Drugs Today. 2008;44:S31–4.Google Scholar
- 5.Oxford Centre for Evidence-based Medicine scores (Oxford Centre for Evidence-based Medicine). Levels of evidence and grades of recommendation. 2013. http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/
- 6.World Health Organization (WHO). Annex 1. GRADE evidence profiles. http://www.who.int/hrh/retention/annex1_grade_evidence_profiles.pdf.
- 7.Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. http://handbook.cochrane.org/chapter_12/12_2_1_the_grade_approach.htm.
- 15.• Campbell JD, Perry R, Papadopoulos NG, Krishnan J, Brusselle G, Chisholm A, et al. The REal Life EVidence AssessmeNt Tool (RELEVANT): development of a novel quality assurance asset to rate observational comparative effectiveness research studies. Clin Transl Allergy. 2019;9:21. https://doi.org/10.1186/s13601-019-0256-9. The paper provides a practical example on how to use RWD.CrossRefPubMedPubMedCentralGoogle Scholar
- 16.•• Roche N, Campbell JD, Krishnan JA, Brusselle G, Chisholm A, Bjermer L, et al. Quality standards in respiratory real-life effectiveness research: the REal Life EVidence AssessmeNt Tool (RELEVANT): report from the Respiratory Effectiveness Group-European Academy of Allergy and Clinical Immunology Task Force. Clin Transl Allergy. 2019;9:20. https://doi.org/10.1186/s13601-019-0255-x. The paper provides an expert evaluation of a tool in RWD.CrossRefPubMedPubMedCentralGoogle Scholar
- 17.• Bachert C, Larché M, Bonini S, Canonica GW, Kündig T, Larenas-Linnemann D, et al. Allergen immunotherapy on the way to product-based evaluation -a WAO statement. World Allergy Organ J. 2015;8:29. https://doi.org/10.1186/s40413-015-0078-8. The paper provides new concepts to applied in AIT.CrossRefPubMedPubMedCentralGoogle Scholar
- 18.• Zielen S, Devillier P, Heinrich J, Richter H, Wahn U. Sublingual immunotherapy provides long-term relief in allergic rhinitis and reduces the risk of asthma: a retrospective, real world database analysis. Allergy. 2017;73(1):165–77 1–13. The paper provides an example of new AIT data generated by RWD.CrossRefGoogle Scholar
- 19.• Devillier P, Molimard M, Ansolabehere X, Bardoulat I, Coulombel N, Maurel F, Le Jeunne P, Demoly P. Immunotherapy with grass pollen tablets reduces medication dispensing for allergic rhinitis and asthma: a retrospective database study in France. Allergy. 2018. doi: https://doi.org/10.1111/all.13705. The paper provides an example of new AIT data generated by RWD.
- 21.Kroon AM. The EAMG position on the regulation of existing products for treatment with special reference to named patient products (NPPs). Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M 2003; (94): 7–14; discussion 14–6.Google Scholar